FDA approves Nuvation Bio IBTROZI sNDA, NUVB jumps 6%
The FDA approved Nuvation Bio’s supplemental New Drug Application for IBTROZI (taletrectinib), updating the label for the ROS1 inhibitor ahead of the PDUFA target date. NUVB shares rose more than 6% to $6.130.